Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Co-Diagnostics, Inc. has entered into a securities purchase agreement with institutional investors to sell 1,647,447 shares of common stock in a private placement. The offering is priced at $1.821 per share, with estimated gross proceeds of approximately $3.0 million. The private placement is expected to close on or about May 21, 2026, and includes warrants for additional shares.
SALT LAKE CITY, May 19, 2026 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx”, or the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into a securities purchase…